Retrospective Study of Unresectable Stage III or Stage IV Melanoma Patients Refractory to Immune Check Point and BRAF/MEK Inhibitors, Treated with Triplet Therapy: A Single Institution Experience.

Authors

Hariharasudan Mani MD, Lehigh Valley Health NetworkFollow
Suresh G. Nair MD, Lehigh Valley Health NetworkFollow
Timothy Johnson MD, Lehigh Valley Health NetworkFollow
Darshan Lal MD, Lehigh Valley Health NetworkFollow
Zeeshan Hafeez MD, Lehigh Valley Health NetworkFollow
Hope Kincaid MPH, CPH, Lehigh Valley Health NetworkFollow
Alyson McIntosh MD, Lehigh Valley Health NetworkFollow
Aaron U. Blackham MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

4-2024

Published In/Presented At

Mani, H., Nair, S., Johnson, T., Lal, D., Hafeez, Z., Kincaid, H., McIntosh, A., & Blackham, A. (2024, April). Retrospective Study of Unresectable Stage III or Stage IV Melanoma Patients Refractory to Immune Check Point and BRAF/MEK Inhibitors, Treated with Triplet Therapy: A Single Institution Experience. Presented at Lehigh Valley Health Network.

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Department of Medicine Fellows and Residents, Department of Medicine Faculty, Hematology-Medical Oncology Division, Hematology-Medical Oncology Division Fellows and Residents, Fellows and Residents, Network Office of Research and Innovation, Department of Radiation Oncology

Document Type

Presentation